miRNA-363-3p/DUSP10/JNK轴通过增强DNA损伤修复介导弥漫大B细胞淋巴瘤的化疗耐药
研究通过miRNA与基因表达谱(n=47)及更大队列(n=106)验证,发现miRNA-363-3p高表达与弥漫大B细胞淋巴瘤化疗耐药独立相关。机制上,miRNA-363-3p靶向抑制DUSP10,促进JNK磷酸化,负调控同源重组修复并增强非同源末端连接修复,从而减少多柔比星诱导的凋亡。靶向JNK和PARP1可抑制DNA双链断裂修复、增加凋亡与肿瘤缩小并改善荷瘤小鼠生存。
要点
- miRNA-363-3p高表达与弥漫大B细胞淋巴瘤化疗耐药独立相关,并在更大队列中验证。
- miRNA-363-3p通过靶向DUSP10促进JNK磷酸化,负调控同源重组修复、增强非同源末端连接修复。
- 靶向JNK和PARP1可抑制多柔比星诱导的DNA双链断裂修复,增加凋亡和肿瘤缩小,改善荷瘤小鼠生存。
核心结论
- miRNA-363-3p/DUSP10/JNK轴是弥漫大B细胞淋巴瘤的一种新化疗耐药机制,可能通过靶向治疗逆转。
研究设计与样本
- 研究检测了miRNA与基因表达谱(n=47)以揭示潜在化疗耐药机制和治疗途径。
- 在更大队列(n=106)中验证了miRNA-363-3p高表达与化疗耐药的独立相关性。
- 通过体外和体内实验,采用过表达和CRISPR/Cas9介导的敲除在弥漫大B细胞淋巴瘤细胞系中研究miRNA-363-3p功能。
主要发现
- miRNA-363-3p高表达与化疗耐药独立相关,并在更大队列(n=106)中验证。
- 过表达miRNA-363-3p减少多柔比星诱导的凋亡和肿瘤缩小,CRISPR/Cas9敲除则相反。
- DNA甲基化参与miRNA-363-3p的转录调控。
- DUSP10是miRNA-363-3p的靶点,其抑制促进JNK磷酸化。
- miRNA-363-3p/DUSP10/JNK轴主要与同源重组和DNA修复通路的负调控相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anthracycline-based chemotherapy resistance represents a major challenge in diffuse large B-cell lymphoma (DLBCL). MiRNA and gene expression profiles (n = 47) were determined to uncover potential chemoresistance mechanisms and therapeutic approaches. An independent correlation between high expression of miRNA-363-3p and chemoresistance was observed and validated in a larger cohort (n = 106). MiRNA-363-3p was shown to reduce doxorubicin-induced apoptosis and tumor shrinkage in in vitro and in vivo experiments by ectopic expression and CRISPR/Cas9-mediated knockout in DLBCL cell lines. DNA methylation was found to participate in transcriptional regulation of miRNA-363-3p. Further investigation revealed that dual specificity phosphatase 10 (DUSP10) is a target of miRNA-363-3p and its suppression promotes the phosphorylation of c-Jun N-terminal kinase (JNK). The miRNA-363-3p/DUSP10/JNK axis was predominantly associated with negative regulation of homologous recombination (HR) and DNA repair pathways. Ectopic expression of miRNA-363-3p more effectively repaired doxorubicin-induced double-strand break (DSB) while enhancing non-homologous end joining repair and reducing HR repair. Targeting JNK and poly (ADP-ribose) polymerase 1 significantly inhibited doxorubicin-induced DSB repair, increased doxorubicin-induced cell apoptosis and tumor shrinkage, and improved the survival of tumor-bearing mice. In conclusion, the miRNA-363-3p/DUSP10/JNK axis is a novel chemoresistance mechanism in DLBCL that may be reversed by targeted therapy.
引用
- Zhou W, Xu Y, Zhang J, et al. MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma. Leukemia. 2022. PMID: 35488020. doi:10.1038/s41375-022-01565-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。